{{Rsnum
|rsid=17098707
|Gene=GRK5
|Chromosome=10
|position=121086097
|Orientation=plus
|ReferenceAllele=A
|MissenseAllele=T
|GMAF=0.0879
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|Status=Merged
|Merged=2230345
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 95.2 | 4.8 | 0.0
| HCB | 97.7 | 2.3 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 49.2 | 42.6 | 8.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 97.7 | 2.3 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

This polymorphism is present in the GRK5 gene found on chromosome 10 and leads to a nonsynonymous change at amino acid 41 (Gln41Leu).  The Leu change is more common in African Americans and less common in Europeans.  The GRK5-Leu41 was associated with a decreased mortality in African Americans with heart failure or cardiac ischemia({{PMID|18425130|OA=1
}}).

{{PharmGKB
|RSID=rs17098707
|Name_s=GRK5-Leu41
|Gene_s=GRK5
|Feature=Exon/NonSyn
|Evidence=PubMed ID:18425130
|Annotation=This variant, present in approximately 40% of African Americans, is a nonsynonymous polymorphism of GRK5 that encodes a G protein-coupled receptor kinase in which Leucine is substituted for Glutamine at amino acid position 41. African American subjects with this variant had a longer time to death or cardiac transplantation than those without it, indicating a protective effect of GRK5-Leu 41. In transgenic mice, human GRK5-Leu41 is protective against cardiomyopathy induced by exposure to excessive catecholamine levels. In vitro experiments demonstrate that GRK5-Leu enhances desensitization of catecholamine-stimulated human beta-adrenergic receptors.
|Drugs=
|Drug Classes=BETA BLOCKING AGENTS
|Diseases=Heart Failure
|Curation Level=Curated
|PharmGKB Accession ID=PA161614214
}}

{{PMID Auto
|PMID=16385451
|Title=A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease.
|OA=1
}}

{{PMID Auto
|PMID=19842931
|Title=GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.
|OA=1
}}

{{GET Evidence
|gene=GRK5
|aa_change=Gln41Leu
|aa_change_short=Q41L
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17098707
|overall_frequency_n=1069
|overall_frequency_d=10758
|overall_frequency=0.0993679
|n_genomes=16
|n_genomes_annotated=0
|n_haplomes=17
|n_articles=1
|n_articles_annotated=1
|qualityscore_in_silico=3
|qualitycomment_in_silico=Y
|in_pharmgkb=Y
|pph2_score=0.016
|nblosum100=5
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}